Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region;Impact des protocoles de chimiothérapie administrés pour cancer du sein métastatique sur le coût du traitement et la survie de 371 patientes traitées dans trois établissements de la région Rhône-Alpes

Bulletin du Cancer

Volumn 96, Issue 10, 2009, Pages 929-940

  Trombert Paviot, B ^a   Bachelot, T ^b   Clavreul, G ^c   Jacquin, J P ^c   Mille, D ^c   Rodrigues, J M ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

^b CENTRE LÉON BÉRARD   (France)

^c Institut de Cancerologie de la Loire   (France)

Author keywords

Breast cancer; Cost; Metastasis; Palliative chemotherapy; Survival

Indexed keywords

ANASTROZOLE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; LETROZOLE; MEGESTROL; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; VINBLASTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; BONE TUMOR; BREAST TUMOR; CANCER CENTER; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; ECONOMICS; FEMALE; FRANCE; HEALTH CARE COST; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PALLIATIVE THERAPY; STATISTICS; SURVIVAL;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CANCER CARE FACILITIES; CHI-SQUARE DISTRIBUTION; DIRECT SERVICE COSTS; DRUG COSTS; FEMALE; FRANCE; HOSPITALIZATION; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; PALLIATIVE CARE; SURVIVAL ANALYSIS;

EID: 70350518150     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0920     Document Type: Article

References (18)

1. Remontet L, Estève J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 2003 ; 51 : 3-30.
2. Goldhirsh A, Glick J, Gelber R, Senn HJ. Meetings highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998 ; 90 : 1601-1608 (Pubitemid 28523434)
3. NIH, National Institute of Health. Adjuvant therapy for breast cancer. Bethesda, 1-3 November 2000. Available: URL: http:// Consensus.nih.gov/2000/2000 AdjuvantTherapy Breast Cancer114html.htm.
4. Mauriac L, Luporsi E, Cutuli B, Garbay JR, Giard S, Spyratos F, et al. Fédération nationale des centres de lutte contre le cancer. In : Cancers du sein infiltrants non métastatiques. Paris : John Libbey Eurotext, 2001. Standards : Options & Recommandations, vol 12.
5. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998 ; 352 : 930-942
6. Lévy C, Bonastre J. Le coût de la chimiothérapie. Bull Cancer 2003 ; 90 : 976-982
7. Buron C, Doz M, Livartowski A. Molécules onéreuses. Analyse des dépenses en Île-de-France. Gestions Hosp 2006 ; 453 : 135-140
8. Fagnani F, Colin X, Arveux P, Coudert B, Misset JL. Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer. Bull Cancer 2007 ; 94 : 711-720 (Pubitemid 47413897)
9. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 2004 ; 22 : 3302-3308 (Pubitemid 41103686)
10. http://oncolor.org/referentiels/sein/sein-ttt-meta-arb.htm#tablo -Date de révision : 9 février 2007.
11. Recommandations pour la pratique clinique : Saint-Paul-de-Vence 2007 « cancers du sein ». http://cours-saint-paul.fr/ 10/recommandations/texte-integral.pdf.
12. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005 ; 10 (suppl 3) : 20-29. www.TheOncologist.com. (Pubitemid 43152727)
13. Launois R, Vergnenègre A, Garrigues B. Notions et mesure des coûts en fonction de la perspective choisie. Bull Cancer 2003 ; 90 : 946-954 (Pubitemid 37543923)
14. Institut national du cancer. Analyse économique des coûts du cancer en France. In : Études et expertises. 2007.
15. Institut national du cancer. Rapport sur la situation du cancer en France en 2007. 154 pages. http://www.e-cancer.fr/.
16. Jassem J, Pieńkowski T, Płuzańska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer. Final results of a randomized phase III multicenter trial. J Clin Oncol 2001 ; 19 : 1707-1715 (Pubitemid 32230871)
17. Mille D, Roy T, Carrere MO, Ray I, Ferdjaoui N, Spath HM, et al. Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. J Clin Oncol 2000 ; 18 : 1718-1724 (Pubitemid 30220550)
18. Campone M, Deplanque G, Dohollou N, Gligorov J, Largillier R, Namer M, et al. Cancer du sein métastatique. Oncologie 2008 ; 10 : 136-148